Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Pranisa Thanatattanon

  • Carl Icahn has seized a stake in BMS as rumours of an acquisition swirl


  • Zykadia, a lung cancer drug from Novartis, has been granted Priority Review by the FDA
  • Minoryx has received Orphan Drug Designation from the FDA as well as the EMA for its lead candidate, MIN-102, for neurodegenerative disease
  • A patient has died in Roche‘s hemophilia trial for ACE910 but an investigator concluded the drug was not responsible
  • Researchers at the Leibniz Institute on Aging have characterised a mechanism of gene inactivation that may prevent aging and cancer
  • Bacteria have been engineered to convert carbon dioxide into methane by researchers at the University of Kent

Eric Gevaert

  • Memorial Sloan Kettering Cancer Center has shown that using CRISPR to engineer CAR-T cells gives them “better stamina” than TALEN-engineered cells.
  • The British Medical Journal has published an article warning of the negative impact of the Trump presidency across the Atlantic
  • Germany is about to allow the sale of GMOs without labelling

Snoop Dogg or Real Dog?


Images from ChrisVanLennepPhoto, Curioso, Eric Gevaert and Pranisa Thanatattanon /

Previous post

Interfacing the Brain & Machines: Another Step to a Cyborg Future

Next post

This Biotech in London is Going After the Most Common Eye Disease